Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Preliminary efficacy and safety of TT-01488, a novel, non-covalent, reversible BTK inhibitor, in patients with relapsed/refractory mantle cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

WYWei YangXTXiaoqiong TangFLFei Li

Discussion

Loading...

Member takes

Overview

Phase 1 trial shows 70% response rate in patients with relapsed/refractory mantle cell lymphoma, suggesting potential of BTK inhibitor.

Key Points

  • Evaluate the efficacy and safety of TT-01488 in patients with relapsed/refractory mantle cell lymphoma.
  • Phase 1, open-label, multi-center trial
  • Enrolled patients with relapsed/refractory mantle cell lymphoma
  • Administered TT-01488 as monotherapy across multiple dose levels
  • 70% overall response rate in evaluable patients
  • 13 out of 16 patients treated were non-blastoid subtypes
  • Treatment-related adverse events reported in 87.5% of patients

Cite This Study

Yang et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d481https://doi.org/10.1182/blood-2025-1824
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1An open label, single arm, multicenter phase II study of the efficacy and safety of LP-168 monotherapy for relapsed or refractory mantle cell lymphoma.2024
  2. 2Real-world treatment patterns, patient characteristics, and outcomes of cbtki-based therapies amongst a contemporary cohort of patients with R/R MCL in the United States2025
  3. 3Efficacy and safety of rocbrutinib, the fourth generation bruton's tyrosine kinase inhibitor, in patients with BTK inhibitor pre-treated relapsed or refractory Mantle Cell Lymphoma: Results from a Phase II rock-1 trial2025 · 1 citations
  4. 4BTK Inhibitors for the Treatment of Mantle Cell Lymphoma—Current Status and Perspectives2026
  5. 5Efficacy and safety of rocbrutinib, a highly selective 4th-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory Mantle Cell Lymphoma (R/R MCL): Updated results from the phase 1 study2025